AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8356979 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,200 kJ/d diet with combined aerobic and anaerobic exercise
Number of subjects: 121
Study 8356979 — intervention group
Group type: COMPARATOR
Intervention: 4,200 kJ/d diet
Number of subjects: 121
Study 3630992 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-lactose formula
Number of subjects: 40
Study 3630992 — intervention group
Group type: COMPARATOR
Intervention: Soy formula with sucrose or maltose
Number of subjects: 40
Study 28682122 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal verbal imitations
Number of subjects: 249
Study 28682122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency and connection in mother-infant dyads
Number of subjects: 249
Study 27406638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) prophylaxis administered from 6 weeks of age
Number of subjects: 1298
Study 27406638 — intervention group
Group type: COMPARATOR
Intervention: No cotrimoxazole (CTX) prophylaxis
Number of subjects: 1298
Study 27406638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) prophylaxis
Number of subjects: 1298
Study 24076367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator tiotropium (18 mcg)
Number of subjects: 28
Study 24076367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator salmeterol (50 mcg)
Number of subjects: 28
Study 24076367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg once daily for 2 weeks)
Number of subjects: 28
Study 24076367 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (for 2 weeks)
Number of subjects: 28
Study 24076367 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (4 weeks after cessation of prednisolone)
Number of subjects: 28
Study 24076367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea VAS score after 2 weeks of treatment
Number of subjects: 28
Study 23592936 — intervention group
Group type: EXPERIMENTAL
Intervention: FDTV 2 mg/180 mg once per day
Number of subjects: 40
Study 23592936 — intervention group
Group type: COMPARATOR
Intervention: T 2 mg once per day
Number of subjects: 40
Study 20722328 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT programme
Number of subjects: 686
Study 20722328 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 686
Study 18417461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg once daily plus a calorie-restricted diet
Number of subjects: 0
Study 18417461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg once daily plus a calorie-restricted diet
Number of subjects: 0
Study 18417461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18417461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 0
Study 18417461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg and 5 mg
Number of subjects: 0
Study 15917157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐oestradiol, 300 microg daily
Number of subjects: 132
Study 15917157 — intervention group
Group type: COMPARATOR
Intervention: Transdermal matrix patch 17beta‐oestradiol, 50 microg/day
Number of subjects: 132
Study 14651310 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered intervention for sleep disturbed infants
Number of subjects: 33
Study 11029964 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal feed + rapeseed oil (60 g/kg feed)
Number of subjects: 12
Study 11029964 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal feed + rapeseed oil (60 g/kg feed) + vitamin E (200 mg/kg)
Number of subjects: 12
Study 11029964 — intervention group
Group type: COMPARATOR
Intervention: Basal feed (no added fat or vitamin E)
Number of subjects: 12
Study 8996852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (n = 28)
Number of subjects: 52
Study 8996852 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (n = 24)
Number of subjects: 52
Study 1464126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (bolus 3 micrograms.kg‐1.min‐1 for 5 min and maintenance 0.2 micrograms.kg‐1.min‐1 for 4 hours)
Number of subjects: 47
Study 1464126 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 47
Study 6398126 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 90
Study 6398126 — intervention group
Group type: EXPERIMENTAL
Intervention: Myconazole
Number of subjects: 90
Study 29545462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 29545462 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 26943128 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of six allergenic foods (peanut, cooked egg, cow's milk, sesame, whitefish, and wheat)
Number of subjects: 1303
Study 26943128 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of exclusive breast‐feeding to approximately 6 months of age
Number of subjects: 1303
Study 26943128 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of six allergenic foods
Number of subjects: 1303
Study 24859430 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular supervised aquatic exercise (low-intensity aerobic aquatic exercise, twice a week for 10 years)
Number of subjects: 16
Study 24859430 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 16
Study 24859430 — intervention group
Group type: COMPARATOR
Intervention: Comparison of study groups
Number of subjects: 16
Study 22730113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with thalidomide (200 mg daily) for 12 months
Number of subjects: 108
Study 22730113 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 108
Study 20617214 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH2O PEEP
Number of subjects: 75
Study 20617214 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP)
Number of subjects: 75
Study 17398026 — intervention group
Group type: EXPERIMENTAL
Intervention: <70 Gy
Number of subjects: 1530
Study 17398026 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-74.9 Gy
Number of subjects: 1530
Study 17398026 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-79.9 Gy
Number of subjects: 1530
Study 17398026 — intervention group
Group type: EXPERIMENTAL
Intervention: >=80 Gy
Number of subjects: 1530
Study 15767226 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention
Number of subjects: 162
Study 12031363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with oral nifedipine and deflazacort
Number of subjects: 80
Study 12031363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjunctive treatment)
Number of subjects: 80
Study 9822140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0
Study 9822140 — intervention group
Group type: COMPARATOR
Intervention: Combined thiazide and potassium-sparing diuretic
Number of subjects: 0
Study 7521907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 10 micrograms/kg/d
Number of subjects: 43
Study 7521907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 20 micrograms/kg/d
Number of subjects: 43
Study 7521907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filgrastim)
Number of subjects: 43
Study 7521907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (both doses combined)
Number of subjects: 43
Study 2697435 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant GM-CSF
Number of subjects: 0
Study 2697435 — intervention group
Group type: COMPARATOR
Intervention: Controlled trial (not specified)
Number of subjects: 0
Study 972274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 75
Study 972274 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 75
Study 972274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Tobramycin and Gentamicin)
Number of subjects: 75
Study 31487750 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured inpatient intervention including an education programme
Number of subjects: 81
Study 31487750 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured inpatient intervention
Number of subjects: 81
Study 31714640 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic TDM of newer generation AEDs
Number of subjects: 151
Study 31714640 — intervention group
Group type: COMPARATOR
Intervention: Rescue TDM of newer generation AEDs
Number of subjects: 151
Study 31196813 — intervention group
Group type: EXPERIMENTAL
Intervention: Solithromycin 1000 mg (single dose oral)
Number of subjects: 262
Study 31196813 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg (intramuscular) plus Azithromycin 1000 mg (oral)
Number of subjects: 262
Study 28049079 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended early intervention (Extended EI, 3-year EI)
Number of subjects: 160
Study 28049079 — intervention group
Group type: COMPARATOR
Intervention: Step-down psychiatric care (SC, 2-year EI)
Number of subjects: 160
Study 25670542 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + EPO
Number of subjects: 141
Study 25670542 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 141
Study 23972555 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT) offered by lay counsellors
Number of subjects: 1694
Study 23972555 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT)
Number of subjects: 1694
Study 21130937 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment interventions for complicated grief
Number of subjects: 14
Study 21130937 — intervention group
Group type: COMPARATOR
Intervention: Preventive interventions for complicated grief
Number of subjects: 14
Study 19117900 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 89
Study 19117900 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 89
Study 17474857 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intake (highest quartile)
Number of subjects: 380
Study 17474857 — intervention group
Group type: COMPARATOR
Intervention: Low soy intake (lowest quartile)
Number of subjects: 380
Study 17474857 — intervention group
Group type: COMPARATOR
Intervention: High fiber, fruit, or vegetable intake
Number of subjects: 380
Study 14735173 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 368
Study 14735173 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 368
Study 14735173 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of DA
Number of subjects: 368
Study 11149497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 163
Study 11149497 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole/gentamicin
Number of subjects: 163
Study 9184363 — intervention group
Group type: EXPERIMENTAL
Intervention: iv meropenem 1 g tds
Number of subjects: 161
Study 9184363 — intervention group
Group type: COMPARATOR
Intervention: iv cefotaxime 1 g tds and iv metronidazole 500 mg tds
Number of subjects: 161
Study 1351538 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged chemotherapy (with tamoxifen for postmenopausal patients)
Number of subjects: 1506
Study 1351538 — intervention group
Group type: COMPARATOR
Intervention: Single perioperative cycle
Number of subjects: 1506
Study 1351538 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PeCT)
Number of subjects: 1506
Study 1351538 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1506
Study 3157296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 44
Study 3157296 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 44
Study 3114351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin (16 h/day)
Number of subjects: 12
Study 3114351 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal nitroglycerin (24 h/day)
Number of subjects: 12
Study 3114351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31050809 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalar Age of Blood Index (SBI)
Number of subjects: 0
Study 28436092 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (supplement (+) group)
Number of subjects: 48
Study 28436092 — intervention group
Group type: EXPERIMENTAL
Intervention: No creatine supplementation (supplement (-) group)
Number of subjects: 48
Study 28436092 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 25092530 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT anger management group intervention
Number of subjects: 11
Study 23178541 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade III posteroanterior mobilization (3 cycles of 60s)
Number of subjects: 39
Study 21983766 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg
Number of subjects: 60
Study 21983766 — intervention group
Group type: COMPARATOR
Intervention: valsartan 160 mg
Number of subjects: 60
Study 18434906 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding within 24 hours of admission
Number of subjects: 28
Study 18434906 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding on day 4 of admission
Number of subjects: 28
Study 16931217 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily sevelamer dosing
Number of subjects: 24
Study 16931217 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily sevelamer dosing
Number of subjects: 24
Study 14519149 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-treated asthmatics
Number of subjects: 0
Study 14519149 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated asthmatics
Number of subjects: 0
Study 14519149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined asthma groups (both budesonide and placebo)
Number of subjects: 0
Study 14519149 — intervention group
Group type: COMPARATOR
Intervention: Non-asthmatics
Number of subjects: 0
Study 11110230 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/100 mg
Number of subjects: 1161
Study 11110230 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/16 mg
Number of subjects: 1161
Study 11110230 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/50 mg plus HCTZ 12.5 mg
Number of subjects: 1161
Study 11110230 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg plus HCTZ 12.5 mg
Number of subjects: 1161
Study 8882193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Number of subjects: 120
Study 8882193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Number of subjects: 120
Study 1407887 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (75 micrograms)
Number of subjects: 118
Study 1407887 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms)
Number of subjects: 118
Study 1407887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combined hormone replacement therapy (various regimens)
Number of subjects: 118
Study 1407887 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (10 mg)
Number of subjects: 118
Study 1407887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (1 mg)
Number of subjects: 118
Study 1407887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 4061431 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment with follow-up interviews
Number of subjects: 48
Study 4061431 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 48
Study 4061431 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal analyses of drinking behavior data
Number of subjects: 48
Study 30661249 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks (Q4W)
Number of subjects: 0
Study 30661249 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (Q8W)
Number of subjects: 0
Study 30661249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30661249 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg Q8W
Number of subjects: 0
Study 30661249 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 29781302 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional Family-Based Treatment (FBT)
Number of subjects: 69
Study 29781302 — intervention group
Group type: COMPARATOR
Intervention: Alternate Treatment Group
Number of subjects: 69
Study 27737427 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation with positive end-expiratory pressure valve
Number of subjects: 28
Study 27737427 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation without positive end-expiratory pressure valve
Number of subjects: 28
Study 27737427 — intervention group
Group type: COMPARATOR
Intervention: Manual hyperinflation (both with and without valve)
Number of subjects: 28
Study 25010302 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-crank exercise program (12 weeks, 3 sessions/week, moderate intensity 50-65% HRR)
Number of subjects: 17
Study 25010302 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-crank exercise program (12 weeks, 3 sessions/week)
Number of subjects: 17
Study 22352947 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-exposed intervention group (watched programming with media intervention)
Number of subjects: 228
Study 22352947 — intervention group
Group type: COMPARATOR
Intervention: Control group (watched programming without media intervention)
Number of subjects: 228
Study 22352947 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-exposed intervention group
Number of subjects: 228
Study 20522617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment after 1 week
Number of subjects: 0
Study 20522617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment after 2 to 3 weeks
Number of subjects: 0
Study 18161896 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey-impregnated dressings
Number of subjects: 368
Study 18161896 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 368
Study 12378193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase-treated feeds
Number of subjects: 130
Study 12378193 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard feeds)
Number of subjects: 130
Study 9857457 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tracking rate of 130 bpm in group II
Number of subjects: 20
Study 9857457 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tracking rate of 110 bpm in group I
Number of subjects: 20
Study 9857457 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tracking rate of 130 bpm in group I
Number of subjects: 20
Study 9385104 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed tests for treatment effect on time to disease under informative censoring assumptions.
Number of subjects: 0
Study 9385104 — intervention group
Group type: COMPARATOR
Intervention: Weighted log-rank tests.
Number of subjects: 0
Study 9385104 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiparametric estimators for treatment effect.
Number of subjects: 0
Study 2136872 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 224125 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate preparation
Number of subjects: 49
Study 224125 — intervention group
Group type: COMPARATOR
Intervention: Otosporin
Number of subjects: 49
Study 31970563 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (0.066 J/cm2)
Number of subjects: 61
Study 31970563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated fluoride gel and CO2 laser (0.066 J/cm2)
Number of subjects: 61
Study 31970563 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fluoride varnish
Number of subjects: 61
Study 31970563 — intervention group
Group type: COMPARATOR
Intervention: Sealant (control)
Number of subjects: 61
Study 30008038 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Walking (HIIW) - 3 × 5 min bursts at 80% VO2 max, separated by 5 min of walking at 30% VO2 max
Number of subjects: 17
Study 30008038 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Intensity Walking (CMW) - 60% VO2 max for 30 min
Number of subjects: 17
Study 27317101 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantix® (50% permethrin/10% imidacloprid)
Number of subjects: 32
Study 27317101 — intervention group
Group type: EXPERIMENTAL
Intervention: NexGard™
Number of subjects: 32
Study 27317101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravecto™
Number of subjects: 32
Study 27317101 — intervention group
Group type: COMPARATOR
Intervention: Negative placebo control
Number of subjects: 32
Study 24614832 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave diathermy (MD) treatment and exercises
Number of subjects: 39
Study 24614832 — intervention group
Group type: COMPARATOR
Intervention: Exercises only (Control)
Number of subjects: 39
Study 22458574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 3602
Study 22458574 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (UFH + GPI)
Number of subjects: 3602
Study 19628436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 0
Study 19628436 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0
Study 19628436 — intervention group
Group type: COMPARATOR
Intervention: No intervention (baseline non-opioid users)
Number of subjects: 0
Study 17687635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pravastatin (40 mg/day)
Number of subjects: 100
Study 17687635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pravastatin (10 mg) + ezetimibe (10 mg)
Number of subjects: 100
Study 16379629 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 premium diets fed for 4 months each in random order
Number of subjects: 44